How many clinical trials are running for sacituzumab govitecan?

ClinicalTrials.gov lists more than 16 phase 2–4 sacituzumab govitecan trials. This page tracks the 16 largest by enrolment: 11 phase 2, 5 phase 3, and 0 phase 4 among them, with 10 actively recruiting. Updated daily.

Where does this data come from?

All trial data is sourced from ClinicalTrials.gov (CTGov) and refreshed on this page daily.

Can I compare sacituzumab govitecan against other drugs?

Yes. The free ComplyRx Trial Pipeline tool compares up to five drugs side by side on one timeline, with PNG and PDF export. Add any competitor in the search box above.

Antibody-drug conjugates · Live ClinicalTrials.gov data

Sacituzumab govitecan (Trodelvy) clinical trial pipeline

The timeline below tracks the 16 largest phase 2–4 sacituzumab govitecan trials on ClinicalTrials.gov by enrolment, 10 of them actively recruiting. The next phase 3 primary completion among them is expected Jun 2027. Refreshed daily — add up to four competitors to compare pipelines side by side.

16+

Major trials tracked

Phase 3 trials

Actively recruiting

Jun 2027

Next phase 3 primary completion

5,895

Participants across trials

Gilead Sciences

Lead sponsor by trial count

sacituzumab govitecan (16)16 active2020–2032

Hide completed

sacituzumab govitecan

Key

Actual date

Anticipated

Forecast to primary completion

RecruitingActive, not recruitingNot yet recruitingTerminated

'20

'21

'22

'23

'24

'25

'26

'27

'28

'29

'30

'31

'32

sacituzumab govitecan

Sacituzumab Govitecan +/- Pembrolizumab in Metastatic TNBCP2

Sacituzumab Govitecan +/- Pembrolizumab In HR+ / HER2 - MBCP2

Scalp Cooling in MBCP2

EVOKE-01P3

ELEVATE TNBCP2

A Study of the Safety and Efficacy of Various Combinations of Avelumab as Therapy in Locally Advanced or Metastatic Urothelial Carcinoma (JAVELIN Bladder Medley)P2

Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy (ASCENT-05/AFT-65 OptimICE-RD/GBG 119/NSABP B-63)P3

Liquid-biopsy Informed Platform Trial to Evaluate CDK4/6-inhibitor Resistant ER+/HER2- Metastatic Breast CancerP2

Circulating Tumor DNA to Guide Changes in Standard of Care ChemotherapyP2

ASCENT-GYN-01P3

Personalized Antibody-Drug Conjugate Therapy Based on RNA and Protein Testing for the Treatment of Advanced or Metastatic Solid Tumors (The ADC MATCH Screening and Treatment Trial)P2

Optimal Application Timing of ADC Drugs for Advanced Breast CancerP2

OASISP2

A Study Comparing the Combination of Pembrolizumab and Sacituzumab Govitean-hziy Versus Standard of Care in the Treatment of Advanced Urothelial CancerP3

A Phase III Study of JSKN016 Versus Treatment of Physician's Choice in Patients With Triple-Negative Breast Cancer Who Have Failed Standard of CareP3

SCARLET-ICEP2

Upcoming readouts

11 ahead · sacituzumab govitecan

Select a trial to load its full ClinicalTrials.gov record.

Key sacituzumab govitecan trials

Top 12 of the 16 tracked phase 2–4 trials, ordered by phase and status. Each links to its full ClinicalTrials.gov record.

Trial	Title	Phase	Status	Primary completion
NCT05633654	Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice in Patients With …	Phase 3	Recruiting	Jun 2027
NCT06524544	A Study Comparing the Combination of Pembrolizumab and Sacituzumab Govitean-hziy Versus Standard of Care in th…	Phase 3	Recruiting	Dec 2028
NCT07533123	A Phase III Study of JSKN016 Versus Treatment of Physician's Choice in Patients With Triple-Negative Breast Ca…	Phase 3	Recruiting	Mar 2029
NCT05089734	EVOKE-01 — Study of Sacituzumab Govitecan (SG) Versus Docetaxel in Participants With Advanced or Metastatic Non-Small Cel…	Phase 3	Active, not recruiting	Nov 2023
NCT06486441	ASCENT-GYN-01 — Study of Sacituzumab Govitecan Versus Treatment of Physician's Choice in Participants With Endometrial Cancer …	Phase 3	Active, not recruiting	Jun 2029
NCT07657130	Optimal Application Timing of ADC Drugs for Advanced Breast Cancer	Phase 2	Recruiting	Jun 2026
NCT04468061	Sacituzumab Govitecan +/- Pembrolizumab in Metastatic TNBC	Phase 2	Recruiting	Apr 2027
NCT05601440	Liquid-biopsy Informed Platform Trial to Evaluate CDK4/6-inhibitor Resistant ER+/HER2- Metastatic Breast Cance…	Phase 2	Recruiting	Dec 2027
NCT06311214	Personalized Antibody-Drug Conjugate Therapy Based on RNA and Protein Testing for the Treatment of Advanced or…	Phase 2	Recruiting	Mar 2028
NCT04986579	Scalp Cooling in MBC	Phase 2	Recruiting	Jun 2028
NCT05770531	Circulating Tumor DNA to Guide Changes in Standard of Care Chemotherapy	Phase 2	Recruiting	Aug 2028
NCT07259226	OASIS — Optimal Methods to Characterize ADC Resistance in Solid Tumors and Identify Clinically Useful Biomarkers	Phase 2	Recruiting	Nov 2030

Compare sacituzumab govitecan vs trastuzumab deruxtecan Compare sacituzumab govitecan vs datopotamab deruxtecan

FAQ

How many clinical trials are running for sacituzumab govitecan?: ClinicalTrials.gov lists more than 16 phase 2–4 sacituzumab govitecan trials. This page tracks the 16 largest by enrolment: 11 phase 2, 5 phase 3, and 0 phase 4 among them, with 10 actively recruiting. Updated daily.
Where does this data come from?: All trial data is sourced from ClinicalTrials.gov (CTGov) and refreshed on this page daily.
Can I compare sacituzumab govitecan against other drugs?: Yes. The free ComplyRx Trial Pipeline tool compares up to five drugs side by side on one timeline, with PNG and PDF export. Add any competitor in the search box above.

Join the waitlist

Be the first to access ComplyRx

We'll let you know as soon as your spot opens to use ComplyRx.

By joining, you agree to our Privacy Policy.

Upcoming readouts

Key sacituzumab govitecan trials

Related drug pipelines

FAQ

Be the first to access ComplyRx